EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial

Run-Cong Nie iD, Ying Jin iD, Cheng-Cai Liang, Yuan-Fang Li iD, Ying-Bo Chen, Xiao-Wei Sun, Wen-Long Guan, Zi-Xian Wang iD, Hai-Bo Qiu iD, Wei Wang, Shi Chen, Dong-Sheng Zhang und 15 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-02842 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Run-Cong Nie und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical R…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NEOSUMMIT-01 trial previously showed that adding the PD-1 antibody toripalimab to perioperative chemotherapy improved the pathologic response in patients with locally advanced gastric or gastroesophageal junction cancer. Here, we present the event-free survival (EFS) and overall survival (OS) after extended follow-up. A total of 108 patients were enrolled (toripalimab plus chemotherapy, n = 54; chemotherapy alone, n = 54). At the data cutoff date (August 29, 2025), the median follow-up was 43.2 months (interquartile range: 36.6-53.7). The 3-year EFS was 74.7% (95% CI, 63.6% to 87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI, 43.3% to 73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.51 (95% CI, 0.27 to 0.98; P = .044). The 3-year OS was 81.3% (95% CI, 71.4% to 92.4%) versus 72.2% (95% CI, 61.2% to 85.2%), respectively, with an HR of 0.45 (95% CI, 0.21 to 0.95; P = .036). The survival benefits were consistent across most predefined subgroups and were maintained in the analysis excluding patients with dMMR. In conclusion, perioperative toripalimab plus chemotherapy significantly improved 3-year EFS and OS compared with chemotherapy alone, suggesting it as a promising treatment option for patients with locally advanced gastric or gastroesophageal junction cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedFollow-Up Studies

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
  • Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China.
  • Department of Gastric Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
  • Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
  • Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.

ORCID-Profile: Run-Cong Nie, Ying Jin, Yuan-Fang Li, Zi-Xian Wang, Hai-Bo Qiu, Mu-Yan Cai, Ji-Bin Li, Xiong-Wen Tang, Feng Wang, Rui-Hua Xu, Shu-Qiang Yuan

Zitieren

APA

Nie, R. C., Jin, Y., Liang, C. C., Li, Y. F., Chen, Y. B., Sun, X. W., Guan, W. L., Wang, Z. X., Qiu, H. B., Wang, W., Chen, S., Zhang, D. S., Ling, Y. H., Xi, S. Y., Cai, M. Y., Chi, J., Yang, Q. X., Liu, Z. M., Guan, Y. X., …, & Yuan, S. Q. (2026). Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02842

Vancouver

Nie RC, Jin Y, Liang CC, Li YF, Chen YB, Sun XW, et al. Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02842

BibTeX
@article{Nie2026,
  author = {Nie, Run-Cong and Jin, Ying and Liang, Cheng-Cai and Li, Yuan-Fang and Chen, Ying-Bo and Sun, Xiao-Wei and Guan, Wen-Long and Wang, Zi-Xian and Qiu, Hai-Bo and Wang, Wei and Chen, Shi and Zhang, Dong-Sheng and Ling, Yi-Hong and Xi, Shao-Yan and Cai, Mu-Yan and Chi, Jun and Yang, Qiu-Xia and Liu, Zhi-Min and Guan, Yuan-Xiang and Chen, Yong-Ming and Li, Ji-Bin and Tang, Xiong-Wen and Peng, Jun-Sheng and Wang, Feng and Zhou, Zhi-Wei and Xu, Rui-Hua and Yuan, Shu-Qiang},
  title = {Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-02842}
}
Kostenlos starten →